All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: Zyesami
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2021
Details:
The objective of the current study is to determine whether RLF-100™, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-19-infected individuals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
Half-century-old aviptadil, studied over the years for a variety of uses including erectile dysfunction and pulmonary fibrosis, was part of Relief's portfolio when the COVID-19 pandemic began, prompting the company to test it against the new coronavirus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
NeuroRx and Relief Therapeutics have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Relief, NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The committee identified no safety concerns and viewed the study as capable of reaching its prespecified endpoint in potentially proving that RLF-100™ is superior to placebo in achieving recovery from Respiratory Failure in patients with Critical COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Overall, 81% of RLF-100™-treated patients survived beyond 60 days, compared to 17% of control patients. Patients treated with RLF-100™ demonstrated a 9-fold increased probability of survival and recovery from respiratory failure, with a high degree of statistical significance.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: NeuroRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 30, 2020
Details:
NeuroRx and Relief, are leading US and EU commercialization plans. They have now contracted with Nephron Pharmaceuticals to manufacture commercial supplies of RLF-100™ to ensure sufficient supplies to treat 1 million patients, should the drug prove effective in the studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: NeuroRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 21, 2020
Details:
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Recipient: NeuroRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aviptadil
Therapeutic Area: Infections and Infectious Diseases Product Name: RLF-100
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
